BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation

Lin Wang, Paul Park, Frank La Marca, Khoi Than, Chia Ying Lin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: We have previously shown that BMP-2 induces bone formation and inhibits tumorigenicity of cancer stem cells (CSCs) in a human osteosarcoma OS99-1 cell line. In this study, we sought to determine whether BMP-2 can similarly induce bone formation and inhibit the tumorigenicity of renal CSCs identified based on aldehyde dehydrogenase (ALDH) activity in renal cell carcinoma (RCC) cell lines and primary tumors.Methods: Using a xenograft model in which cells from human RCC cell lines ACHN, Caki-2, and primary tumors were grown in NOD/SCID mice, renal CSCs were identified as a subset of ALDHbr cells. The ALDHbr cells possessed a greater colony-forming efficiency, higher proliferative output, increased expression of stem cell marker genes Oct3/4A, Nanog, renal embryonic marker Pax-2, and greater tumorigenicity compared to cells with low ALDH activity (ALDHlo cells), generating new tumors with as few as 25 cells in mice.Results: In vitro, BMP-2 was found to inhibit the ALDHbr cell growth, down-regulate the expression of embryonic stem cell markers, and up-regulate the transcription of osteogenic markers. In vivo, all animals receiving a low number of ALDHbr cells (5 × 103) from ACHN, Caki-2, and primary tumor xenografts treated with 30 µg BMP-2 per animal showed limited tumor growth with significant bone formation, while untreated cells developed large tumor masses without bone formation.Conclusions: These results suggest that BMP-2 inhibits the tumor-initiating ability of renal CSCs and induces osseous bone formation. BMP-2 may therefore provide a beneficial strategy for human RCC treatment by targeting the CSC-enriched population.

Original languageEnglish (US)
Pages (from-to)1013-1024
Number of pages12
JournalJournal of Cancer Research and Clinical Oncology
Volume141
Issue number6
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Kidney Neoplasms
Osteogenesis
Neoplasms
Renal Cell Carcinoma
Aldehyde Dehydrogenase
Heterografts
Cell Line
Inbred NOD Mouse
SCID Mice
Osteosarcoma
Embryonic Stem Cells
Growth
Tumor Cell Line
Up-Regulation
Stem Cells
Down-Regulation
Cell Count
Kidney

Keywords

  • Aldehyde dehydrogenase
  • BMP-2
  • Cancer stem cells
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. / Wang, Lin; Park, Paul; La Marca, Frank; Than, Khoi; Lin, Chia Ying.

In: Journal of Cancer Research and Clinical Oncology, Vol. 141, No. 6, 01.06.2015, p. 1013-1024.

Research output: Contribution to journalArticle

Wang, Lin ; Park, Paul ; La Marca, Frank ; Than, Khoi ; Lin, Chia Ying. / BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. In: Journal of Cancer Research and Clinical Oncology. 2015 ; Vol. 141, No. 6. pp. 1013-1024.
@article{035acc13de554d818994727b970448e1,
title = "BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation",
abstract = "Purpose: We have previously shown that BMP-2 induces bone formation and inhibits tumorigenicity of cancer stem cells (CSCs) in a human osteosarcoma OS99-1 cell line. In this study, we sought to determine whether BMP-2 can similarly induce bone formation and inhibit the tumorigenicity of renal CSCs identified based on aldehyde dehydrogenase (ALDH) activity in renal cell carcinoma (RCC) cell lines and primary tumors.Methods: Using a xenograft model in which cells from human RCC cell lines ACHN, Caki-2, and primary tumors were grown in NOD/SCID mice, renal CSCs were identified as a subset of ALDHbr cells. The ALDHbr cells possessed a greater colony-forming efficiency, higher proliferative output, increased expression of stem cell marker genes Oct3/4A, Nanog, renal embryonic marker Pax-2, and greater tumorigenicity compared to cells with low ALDH activity (ALDHlo cells), generating new tumors with as few as 25 cells in mice.Results: In vitro, BMP-2 was found to inhibit the ALDHbr cell growth, down-regulate the expression of embryonic stem cell markers, and up-regulate the transcription of osteogenic markers. In vivo, all animals receiving a low number of ALDHbr cells (5 × 103) from ACHN, Caki-2, and primary tumor xenografts treated with 30 µg BMP-2 per animal showed limited tumor growth with significant bone formation, while untreated cells developed large tumor masses without bone formation.Conclusions: These results suggest that BMP-2 inhibits the tumor-initiating ability of renal CSCs and induces osseous bone formation. BMP-2 may therefore provide a beneficial strategy for human RCC treatment by targeting the CSC-enriched population.",
keywords = "Aldehyde dehydrogenase, BMP-2, Cancer stem cells, Renal cell carcinoma",
author = "Lin Wang and Paul Park and {La Marca}, Frank and Khoi Than and Lin, {Chia Ying}",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s00432-014-1883-0",
language = "English (US)",
volume = "141",
pages = "1013--1024",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation

AU - Wang, Lin

AU - Park, Paul

AU - La Marca, Frank

AU - Than, Khoi

AU - Lin, Chia Ying

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Purpose: We have previously shown that BMP-2 induces bone formation and inhibits tumorigenicity of cancer stem cells (CSCs) in a human osteosarcoma OS99-1 cell line. In this study, we sought to determine whether BMP-2 can similarly induce bone formation and inhibit the tumorigenicity of renal CSCs identified based on aldehyde dehydrogenase (ALDH) activity in renal cell carcinoma (RCC) cell lines and primary tumors.Methods: Using a xenograft model in which cells from human RCC cell lines ACHN, Caki-2, and primary tumors were grown in NOD/SCID mice, renal CSCs were identified as a subset of ALDHbr cells. The ALDHbr cells possessed a greater colony-forming efficiency, higher proliferative output, increased expression of stem cell marker genes Oct3/4A, Nanog, renal embryonic marker Pax-2, and greater tumorigenicity compared to cells with low ALDH activity (ALDHlo cells), generating new tumors with as few as 25 cells in mice.Results: In vitro, BMP-2 was found to inhibit the ALDHbr cell growth, down-regulate the expression of embryonic stem cell markers, and up-regulate the transcription of osteogenic markers. In vivo, all animals receiving a low number of ALDHbr cells (5 × 103) from ACHN, Caki-2, and primary tumor xenografts treated with 30 µg BMP-2 per animal showed limited tumor growth with significant bone formation, while untreated cells developed large tumor masses without bone formation.Conclusions: These results suggest that BMP-2 inhibits the tumor-initiating ability of renal CSCs and induces osseous bone formation. BMP-2 may therefore provide a beneficial strategy for human RCC treatment by targeting the CSC-enriched population.

AB - Purpose: We have previously shown that BMP-2 induces bone formation and inhibits tumorigenicity of cancer stem cells (CSCs) in a human osteosarcoma OS99-1 cell line. In this study, we sought to determine whether BMP-2 can similarly induce bone formation and inhibit the tumorigenicity of renal CSCs identified based on aldehyde dehydrogenase (ALDH) activity in renal cell carcinoma (RCC) cell lines and primary tumors.Methods: Using a xenograft model in which cells from human RCC cell lines ACHN, Caki-2, and primary tumors were grown in NOD/SCID mice, renal CSCs were identified as a subset of ALDHbr cells. The ALDHbr cells possessed a greater colony-forming efficiency, higher proliferative output, increased expression of stem cell marker genes Oct3/4A, Nanog, renal embryonic marker Pax-2, and greater tumorigenicity compared to cells with low ALDH activity (ALDHlo cells), generating new tumors with as few as 25 cells in mice.Results: In vitro, BMP-2 was found to inhibit the ALDHbr cell growth, down-regulate the expression of embryonic stem cell markers, and up-regulate the transcription of osteogenic markers. In vivo, all animals receiving a low number of ALDHbr cells (5 × 103) from ACHN, Caki-2, and primary tumor xenografts treated with 30 µg BMP-2 per animal showed limited tumor growth with significant bone formation, while untreated cells developed large tumor masses without bone formation.Conclusions: These results suggest that BMP-2 inhibits the tumor-initiating ability of renal CSCs and induces osseous bone formation. BMP-2 may therefore provide a beneficial strategy for human RCC treatment by targeting the CSC-enriched population.

KW - Aldehyde dehydrogenase

KW - BMP-2

KW - Cancer stem cells

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84937965099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937965099&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1883-0

DO - 10.1007/s00432-014-1883-0

M3 - Article

C2 - 25431339

AN - SCOPUS:84937965099

VL - 141

SP - 1013

EP - 1024

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 6

ER -